Two-Year Outcomes with Self-Expanding TAVR

Consider transfemoral transcatheter aortic valve replacement as the first-line therapy for patients with an increased risk for poor surgical outcomes.

Transcatheter aortic valve replacement (TAVR) has become the standard of care in patients who are at extreme risk for complications from surgery. Optimistically, a continuation of technology iteration and improvement might result in a survival advantage, as previously suggested by a study of a self-expanding TAVR device (NEJM JW Cardiol May 2014 and J Am Coll Cardiol 2014 Mar 13; [e-pub] and N Engl J Med 2014 Mar 29; [e-pub]). Now, researchers examined longer-term clinical outcomes to check whether this mortality benefit is sustained.

A total of 797 patients (mean age, 83 years; 48% female) underwent randomization to TAVR with a self-expanding valve or surgery at 45 centers in the U.S. The researchers evaluated the 2-year clinical and echoca…

Reviewing Author

Beat J. Meyer, MD

Disclosures

Leadership positions in professional societiesBern Heart Foundation (President); International Academy of Medicine, Bern, Switzerland (Director)

Beat J. Meyer, MD

Disclosures

Leadership positions in professional societiesBern Heart Foundation (President); International Academy of Medicine, Bern, Switzerland (Director)

Two-Year Outcomes with Self-Expanding TAVR

Topics

Reviewing Author